Private Equity

Updated:

Syno Capital

Syno Capital is a global healthcare and biotech investment firm based in New York City, emphasizing cross-border collaborations between the United States and...

Syno Capital logo

Syno Capital

Syno Capital is a global healthcare and biotech investment firm based in New York City, emphasizing cross-border collaborations between the United States and China. The firm focuses on investments in healthcare, biotech, and related sectors. It was co-founded by Dr. Justin Xiang and Joseph Weilgus.

General information

Firm type

Private Equity

Year founded

2015

Location

Region

North America

Country

United States

City

New York

Corporate office

New York, United States

Principals

Robert D. Weist

Managing Member

Raymond J. K. Ma

Managing Director

Sector focus

Enterprise SoftwareFinancial ServicesHealthcare ServicesIndustrial Tech

Frequently asked questions

Who runs investment decisions at Syno Capital?

Investment decisions are run by Managing Member Robert D. Weist, who founded the firm, alongside Managing Director Raymond J. K. Ma. Weist's prior operating roles at American Express and Lehman Brothers inform the firm's hands-on governance model. The compact leadership structure ensures that every allocation requires the direct approval of principals who remain involved in post-acquisition operations.

How does Syno Capital source its deal flow?

Syno sources proprietary deal flow through a relationship-driven network rather than a large internal origination team. The firm targets founder-owned and family-run businesses in the lower middle market where auction processes are less common. Syno's principals cultivate direct relationships with industry executives, intermediaries, and corporate carve-out sponsors, focusing on situations where an operator-investor is seen as a strategic advantage rather than financial engineering.

Does Syno Capital participate in fund commitments or only direct deals?

Syno's primary investment posture is direct, using its own balance-sheet capital to acquire majority or significant minority stakes in portfolio companies. The firm does not publicly market a fund-of-funds program and does not list itself as a limited partner in external private equity vehicles. Its model is structured around direct platform investments, with co-investment opportunities occasionally extended to select aligned investors on a deal-by-deal basis.

What is Syno Capital's typical hold period for a portfolio company?

Syno operates without the standard 3-to-5-year exit clock that constrains most institutional fund models, allowing for multi-year value creation plans. The firm's stated preference is to improve operational performance and grow earnings over extended hold periods before seeking a liquidity event. This permanent or semi-permanent capital approach gives management teams the runway to execute long-term strategic transformations.

What investment size does Syno Capital typically target?

Syno targets lower-middle-market companies with enterprise values that can support a concentrated deployment per platform, though specific check-size ranges are not publicly disclosed. The firm's preference for a concentrated portfolio means each investment receives a meaningful allocation, avoiding the commoditized auction segment of the market. Its transaction sizes align with founder-owned businesses transitioning from growth stage to institutional maturity.

Which sectors does Syno Capital explicitly avoid?

Syno does not publicly disclose an explicit exclusion list, but its portfolio orientation suggests avoidance of early-stage venture, deep cyclical natural resources, and heavily regulated utilities. The firm's stated focus on technology-enabled business services, software, financial services, and healthcare implicitly avoids sectors such as consumer packaged goods, biotech drug discovery, and real estate development where its operational DNA would be less differentiated.

How is Syno Capital different from a traditional growth equity fund?

Syno differs from a traditional growth equity fund in both portfolio construction and governance. Standard growth equity funds hold 15 to 30 minority positions and rely on board observation rights; Syno operates a concentrated portfolio of fewer platforms with direct operational involvement. The firm's principals embed governance designed to drive post-close transformation, making it structurally more akin to a permanent holding company than a commingled drawdown fund.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More New York Private Equity profiles